Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Tumor regression concomitant with steroid-refractory GvHD highlights the pitfalls of PD-1 blockade following allogeneic hematopoietic stem cell transplantation

Bone Marrow Transplantation volume 52, pages 759–761 (2017)Cite this article

Subjects

For Hodgkin lymphoma (HL) patients who fail front-line therapy, salvage regimens including autologous and allogeneic hematopoietic stem cell transplant (alloHSCT) may cure select patients, although relapse remains a significant cause of transplant failure. Treatment strategies aimed at bolstering post-transplant immunity to both prevent and treat relapse following alloHSCT are of significant interest, especially immune checkpoint inhibitors such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death 1 (PD-1) monoclonal Abs.

Programmed death ligand 1 (PD-L1) binds to its cognate receptor, PD-1, found on activated T cells, resulting in suppression of T-cell activation and proliferation. Classical Hodgkin lymphoma (cHL) is characterized by tumor-infiltrating T cells expressing PD-1 while surrounding malignant Reed-Sternberg (RS) cells.1 RS cells constitutively express PD-L1, although amplification of chromosome 9p24.1 and its induction by JAK2 results in increased expression.2, 3 Blockade of the PD-L1/PD-1 pathway restores antitumor activity of CD4+ HL-infiltrating T cells and IFN-γ production.1 The PD-1 inhibitor, nivolumab, initially showed remarkable efficacy with an overall response rate (ORR) of 87% in a phase 1 study of heavily pretreated relapsed/refractory HL patients, excluding allotransplant patients.4 The ongoing phase 2 study of nivolumab in HL patients who failed to respond to autologous HSCT and brentuximab recently reported an ORR of >66% and recent use of pembrolizumab phase I data in similar patients revealed an ORR of 65%.5, 6 These studies excluded allotransplant recipients based upon evidence that prior murine models demonstrated mice subjected to PD-1/PD-L1 blockade developed rapid, lethal acute GvHD (aGvHD).7

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Yamamoto R, Nishikori M, Kitawaki T, Sakai T, Hishizawa M, Tashima M et al. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 2008; 111: 3220–3224.

    Article  CAS  Google Scholar 

  2. Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O’Donnell E et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010; 116: 3268–3277.

    Article  CAS  Google Scholar 

  3. Green MR, Rodig S, Juszczynski P, Ouyang J, Sinha P, O’Donnell E et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res 2012; 18: 1611–1618.

    Article  CAS  Google Scholar 

  4. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 2015; 372: 311–319.

    Article  Google Scholar 

  5. Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentere, multicohort, single-arm phase 2 trial. Lancet Oncol 2016; 17: 1283–1294.

    Article  CAS  Google Scholar 

  6. Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol 2016; 34: 3733–3739.

    Article  CAS  Google Scholar 

  7. Saha A, Aoyama K, Taylor P, Koehn BH, Veenstra RG, Panoskaltsis-Mortari A et al. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. Blood 2013; 122: 3062–3073.

    Article  CAS  Google Scholar 

  8. Villasboas JC, Ansell SM, Witzig TE . Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective. Oncotarget 2016; 7: 13260–13264.

    Article  Google Scholar 

  9. Angenendt L, Schliemann C, Lutz M, Rebber E, Schulze AB, Weckesser M et al. Nivolumab in a patient with refractory Hodgkin’s lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant 2016; 51: 443–445.

    Article  CAS  Google Scholar 

  10. Herbaux C, Gauthier J, Brice P, Fornecker L, Bouabdallah K, Manson G et al. Nivolumab is effective and reasonably safe in relapsed or refractory Hodgkin’s lymphoma after allogeneic hematopoietic cell transplantation: a study from the Lysa and SFGM-TC. Blood 2015; 126: 3979.

    Google Scholar 

  11. Singh AK, Porrata LF, Alijitawi O, Lin T, Shune L, Ganguly S et al. Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin’s lymphoma. Bone Marrow Transplant 2016; 51: 1268–1270.

    Article  CAS  Google Scholar 

  12. Mori S, Ahmed W, Patel RD, Dohrer AL . Steroid refractory acute liver GVHD in a Hodgkin’s patient after allogeneic stem transplant cell transplantation following treatment with anti PD-1 antibody, nivolumab, for relapsed disease. Biol Blood Marrow Transplant 2016; 22: S392–S393.

    Article  Google Scholar 

  13. Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A et al. Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med 2016; 375: 143–153.

    Article  CAS  Google Scholar 

  14. Srinivasan R, Chakrabarti S, Walsh T, Igarashi T, Takahashi Y, Kleiner D et al. Improved survival in steroid-refractory acute graft versus host disease after non-myeloblative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis. Br J Haematol 2004; 124: 777–786.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by the Intramural Research Program of the National Heart, Lung and Blood Institute of the National Institutes of Health.

Author information

Authors and Affiliations

  1. Department of Hematology, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA

    E McDuffee, G Aue, L Cook, C Ramos-Delgado, R Shalabi, T Worthy, P Vo & R W Childs

Authors
  1. E McDuffee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G Aue
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L Cook
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Ramos-Delgado
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R Shalabi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T Worthy
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P Vo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. R W Childs
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R W Childs.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

McDuffee, E., Aue, G., Cook, L. et al. Tumor regression concomitant with steroid-refractory GvHD highlights the pitfalls of PD-1 blockade following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 52, 759–761 (2017). https://doi.org/10.1038/bmt.2016.346

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2016.346

This article is cited by

Search

Advanced search

Quick links